The role of heparin in reducing in-hospital complications and three-month mortality rates in hospitalized COVID-19 patients

Eur J Intern Med. 2022 Jul:101:124-127. doi: 10.1016/j.ejim.2022.03.015. Epub 2022 Mar 16.

Authors

F Calabretta¹, P S Preti², M Russo², C Klersy³, A Di Sabatino²

Affiliations

¹ Department of Internal Medicine, IRCCS Policlinico San Matteo Foundation, University of Pavia, Pavia, Italy. Electronic address: p.preti@smatteo.pv.it.
² Department of Internal Medicine, IRCCS Policlinico San Matteo Foundation, University of Pavia, Pavia, Italy.
³ Clinical Epidemiology and Biometry Service. IRCCS Policlinico San Matteo Foundation. Pavia, Italy.

No abstract available

Keywords: Covid-19; Enoxaparin; Myocardial infarction; Venous thrombosis.

Publication types

Letter

MeSH terms

Anticoagulants / therapeutic use
COVID-19*
Enoxaparin
Heparin* / therapeutic use
Hospitals
Humans

Substances

Anticoagulants
Enoxaparin
Heparin